Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Overview | 8 | 1 |
| Therapeutics Development | 9 | 4 |
| Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Products under Development by Stage of Development | 9 | 1 |
| Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Products under Development by Therapy Area | 10 | 1 |
| Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Products under Development by Indication | 11 | 2 |
| Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Products under Development by Companies | 15 | 3 |
| Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Therapeutics Assessment | 18 | 6 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 2 |
| Assessment by Route of Administration | 21 | 2 |
| Assessment by Molecule Type | 23 | 1 |
| Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Companies Involved in Therapeutics Development | 24 | 7 |
| Actelion Ltd | 24 | 1 |
| Arena Pharmaceuticals, Inc. | 25 | 1 |
| AstraZeneca Plc | 26 | 1 |
| Bristol-Myers Squibb Company | 27 | 1 |
| Celgene Corporation | 28 | 1 |
| GlaxoSmithKline Plc | 29 | 1 |
| Novartis AG | 30 | 1 |
| Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Drug Profiles | 31 | 26 |
| AKP-11 Drug Profile | 31 | 2 |
| BMS-986104 Drug Profile | 33 | 1 |
| CBP-307 Drug Profile | 34 | 1 |
| Cenerimod Drug Profile | 35 | 1 |
| CP-9531 Drug Profile | 36 | 1 |
| etrasimod arginine Drug Profile | 37 | 2 |
| NIBR-0213 Drug Profile | 39 | 1 |
| ozanimod hydrochloride Drug Profile | 40 | 6 |
| ponesimod Drug Profile | 46 | 3 |
| siponimod Drug Profile | 49 | 3 |
| Small Molecule to Agonize S1P1 for Multiple Sclerosis Drug Profile | 52 | 1 |
| Small Molecule to Agonize S1PR1 for Multiple Sclerosis Drug Profile | 53 | 1 |
| Small Molecule to Agonize S1PR1 for Ulcerative Colitis Drug Profile | 54 | 1 |
| Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology Drug Profile | 55 | 1 |
| Small Molecule to Modulate S1PR1 for Atopic Dermatitis Drug Profile | 56 | 1 |
| Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Dormant Projects | 57 | 2 |
| Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Discontinued Products | 59 | 1 |
| Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Featured News &Press Releases | 60 | 15 |
| Sep 29, 2016: Actelion To Investigate All-Oral Combination Therapy For Patients With Relapsing Multiple Sclerosis | 60 | 2 |
| Sep 17, 2016: Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients | 62 | 1 |
| Sep 16, 2016: Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS | 63 | 1 |
| Aug 25, 2016: Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS | 64 | 1 |
| Jun 13, 2016: Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug Candidate APD334 | 65 | 1 |
| May 04, 2016: Study Shows Ozanimod as Effective in Treating Ulcerative Colitis | 65 | 1 |
| Mar 18, 2016: Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial | 66 | 2 |
| Feb 18, 2016: Oral Ozanimod 72-Week Phase 2 Results From RADIANCE Trial in Relapsing Multiple Sclerosis Presented At ACTRIMS | 68 | 1 |
| Jan 08, 2016: Suzhou Connect Biopharma Reports Positive Phase 1b Result for Novel S1P1 Modulator CBP-307 for Autoimmune Diseases | 69 | 1 |
| Dec 14, 2015: Akaal Pharma Announces Superior Safety and Comparable Efficacy of Sphingosine 1-Phosphate Receptor-1 (S1P1) Modulator AKP-11 as Compared to Gilenya (Fingolimod) for the Treatment of Multiple Sclerosis | 69 | 1 |
| Dec 14, 2015: US Patents Issued to Akaal Pharma on S1P1 Receptor Modulators Useful for the Treatment of Autoimmune and Inflammatory Diseases | 70 | 1 |
| Oct 26, 2015: Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at UEG Week | 70 | 1 |
| Oct 19, 2015: Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at ACG Plenary Session | 71 | 2 |
| Sep 01, 2015: MS Trial Alert: Investigators Recruiting Worldwide for Phase III Clinical Trial of Oral Ponesimod | 73 | 1 |
| Jul 30, 2015: Suzhou Connect Biopharma Reports Positive Phase 1a Results for CBP-307, a Novel, Orally-active S1P1 Modulator for Autoimmune Diseases | 73 | 2 |
| Appendix | 75 | 2 |
| Methodology | 75 | 1 |
| Coverage | 75 | 1 |
| Secondary Research | 75 | 1 |
| Primary Research | 75 | 1 |
| Expert Panel Validation | 75 | 1 |
| Contact Us | 75 | 1 |
| Disclaimer | 76 | 1 |
